Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case Reports
Immune checkpoint inhibitors (ICIs) improve the outcomes of several types of cancer. However, they are also associated with various immune-related adverse events including myocarditis. ICI-induced myocarditis is a rare, potentially life-threatening adverse event. We herein report two cases of corticosteroid-refractory ICI-induced myocarditis. In both cases, additional immunosuppressive therapies, such as intravenous immunoglobulin and tacrolimus, successfully resolved myocarditis. Given the corticosteroid-refractory nature of these cases, we suggest that prompt addition of other immunosuppressive drugs to corticosteroid therapy should be considered in the treatment of ICI-induced myocarditis.
Authors
- Masaya Shimojima (ORCID: https://orcid.org/0000-0001-9223-6990)
- Akihiro Nishiyama
- Seiji Yano (ORCID: https://orcid.org/0000-0002-6151-2988)
- Hiroshi Kotani (ORCID: https://orcid.org/0000-0002-6001-0636)
- Shinji Takeuchi (ORCID: https://orcid.org/0000-0002-3779-1454)
- Hiroyuki Sakaguchi
- Koushiro Ohtsubo (ORCID: https://orcid.org/0000-0002-4490-4306)
- Chiaki Suzuki (ORCID: https://orcid.org/0000-0002-3287-7857)
- Shigeki Nanjo
- Kaname Yamashita
- Shigeki Sato (ORCID: https://orcid.org/0009-0001-7753-4559)
Institutions
- Kanazawa University (JP)
- Kyoto University (JP)
- Kanazawa University Hospital (JP)
- Kanazawa Medical University Hospital (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2024-09-03
- DOI
- https://doi.org/10.2169/internalmedicine.4162-24
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85